New Protein Characterization Technique Unveiled at Pittcon 2019
Pharmaceutical Technology's In the Lab eNewsletter
Microsaic Systems showcased its new MiD ProteinID point-of-need mass spectrometer at Pittcon in Philadelphia, PA, from March 18–21, 2019.
Microsaic’s MiD ProteinID point-of-need mass spectrometer allows users to verify target proteins, metabolites, by-products and feed-stocks throughout the whole bioprocessing value chain and offers laboratory-level performance on an industrial scale.
By providing deterministic characterization for proteins and small molecules at the point-of-need, the mass spectrometer helps to ensure critical process parameters and critical quality attributes are attained timely, and simultaneously, which is vital for biologics compliance, according to the company.
“Our MiD ProteinID system is a process analytical game changer. Bioprocessing operators can now monitor feedstocks, metabolites, and target proteins in just one measurement, accelerating time-to-market for new biologics and assisting in process and product compliance,” said Glenn Tracey, CEO, Microsaic Systems, in a company press release. “Mass spectrometry can now offer superlative performance to high-value manufacturing industries at the point-of-need, providing much greater insights over ubiquitous optical sensors, such as [ultraviolet], Raman, and [near infrared].”
The mass spectrometer was showcased at booth 4131 at Pittcon 2019 in Philadelphia, PA, which took place from March 17–21, 2019.
Source: Microsaic Systems
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
